Amylon Therapeutics
About Amylon Therapeutics
Amylon Therapeutics targets CNS disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications. The anti-amyloid technology of Amylon allows a focus on different disorders, with a primary focus on HCHWA-D and CAA. Amylon is led by founder Thomas de Vlaam, complemented by a scientific board of experienced scientists and biotech veterans. As a spin-off from the NASDAQ traded ProQR Therapeutics, Amylon enjoys a wealth of knowledge and experience through its shareholders and network.LEADERSHIP:
Founder and CEO: Thomas de Vlaam
2 articles about Amylon Therapeutics
-
Amylon Therapeutics Targeting Central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe Berlin
11/8/2017
Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe Spring 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a J&J Innovation, JLINX community member.
-
ProQR Therapeutics Spins Out CNS-Focused Biotech, Amylon Therapeutics
9/12/2017